HOOKIPA Pharma Appoints Katia Schlienger, M.D., Ph.D., Chief Medical Officer and Malte Peters, M.D., to Board of Directors
15. Dezember 2022 07:00 ET
|
HOOKIPA Pharma Inc.
NEW YORK and VIENNA, Austria, Dec. 15, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary...
HOOKIPA to Participate in The JMP Securities Hematology and Oncology Summit
30. November 2022 07:00 ET
|
HOOKIPA Pharma Inc.
NEW YORK and VIENNA, Austria, Nov. 30, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary...
HOOKIPA Pharma Announces Third Quarter 2022 Financial Results and Provides a Business Update
14. November 2022 07:00 ET
|
HOOKIPA Pharma Inc.
Major oncology collaboration and license agreement secured with Roche to develop HB-700 for KRAS-mutated cancers and an additional undisclosed oncology candidateInvestigational New Drug Application...
HOOKIPA Pharma to Report Third Quarter 2022 Financial Results and Corporate Updates on November 14, 2022
07. November 2022 07:00 ET
|
HOOKIPA Pharma Inc.
NEW YORK and VIENNA, Austria, Nov. 07, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapies based on its proprietary arenavirus...
HOOKIPA to Participate in the Sidoti Micro-Cap Virtual Conference
02. November 2022 07:00 ET
|
HOOKIPA Pharma Inc.
NEW YORK and VIENNA, Austria, Nov. 02, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary...
HOOKIPA announces strategic collaboration and license agreement with Roche to develop novel arenaviral immunotherapy for KRAS-mutated cancers
20. Oktober 2022 07:00 ET
|
HOOKIPA Pharma Inc.
Roche to receive license for HOOKIPA’s HB-700 program and option to license a second undisclosed novel arenaviral immunotherapyHOOKIPA to receive $25 million in upfront cash as well as potential...
HOOKIPA Pharma to Participate in Upcoming Investor Conferences in September
07. September 2022 07:00 ET
|
HOOKIPA Pharma Inc.
NEW YORK and VIENNA, Sept. 07, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapies based on its proprietary arenavirus...
HOOKIPA Pharma Reports Second Quarter 2022 Financial Results and Corporate Updates
11. August 2022 07:00 ET
|
HOOKIPA Pharma Inc.
HB-200 Phase 1 data presented at ASCO met all endpoints in heavily pre-treated head and neck cancer patients; Phase 2 study underwayUS Food and Drug Administration accepted HOOKIPA’s Investigational...
HOOKIPA Pharma to Report Second Quarter 2022 Financial Results on August 11, 2022
04. August 2022 07:00 ET
|
HOOKIPA Pharma Inc.
NEW YORK and VIENNA, Austria, Aug. 04, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapies based on its proprietary arenavirus...
FDA accepts HOOKIPA’s Investigational New Drug Application for HB-300 for the treatment of metastatic castration-resistant prostate cancer
25. Juli 2022 08:00 ET
|
HOOKIPA Pharma Inc.
Novel arenaviral immunotherapy is directed against the prostate cancer targets PAP and PSA; Phase 1/2 trial to commence by early 2023Drug Master File (DMF) accepted to support future FDA submissions ...